# A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

> **NCT02623595** · PHASE2 · WITHDRAWN · sponsor: **Wuhan University**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **RADIATION:** Stereotactic body radiotherapy
- **DRUG:** rhGM-CSF

## Key facts

- **NCT ID:** NCT02623595
- **Lead sponsor:** Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-05
- **Primary completion:** 2019-05
- **Final completion:** 2019-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Patient enrollment was hard mainly due to we need at least three lesions suitable for SBRT
- **Last updated:** 2018-10-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623595, "A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02623595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*